Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

DRG Insight: Hypertension (G7) 6/1/2012 \| published by: Decision Resources ... campaigns and initiatives. The hypertension market, though mature and heavily genericized, offers significant opportunities for blood pressure (BP)-lowering drugs that can prevent the development of cardiovascular disease, cerebrovascular disease, or end-organ damage. The best on-market ... \| more...	$3,000.00
DRG Insights: Hepatitis C (G7) 5/1/2012 \| published by: Decision Resources ... campaigns and initiatives. Hepatitis C virus (HCV) is marked by a relatively large prevalent population and high unmet medical need due to the suboptimal efficacy of current therapy. This high unmet need makes HCV one ... \| more...	$3,000.00
DRG Insight: Colorectal Cancer (G7) 5/1/2012 \| published by: Decision Resources ... campaigns and initiatives. Colorectal cancer (CRC) is one of the most common forms of cancer and in 2010 was the fifth most common cancer-related death worldwide. Over the next ten years the number of incident ... \| more...	$3,000.00
DRG Insights: Benign Prostate Hyperplasia (G7) 5/1/2012 \| published by: Decision Resources ... campaigns and initiatives. Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) affect 159 million men aged 40 or older in the major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, ... \| more...	$3,000.00
DRG Insights: Multiple Sclerosis (G7) 5/1/2012 \| published by: Decision Resources ... campaigns and initiatives. Following the 2010 launch of Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera), the market for disease-modifying multiple sclerosis (MS) therapies has begun a dramatic transformation. A broad array of new and promising anti-inflammatory treatments ... \| more...	$3,000.00
DRG Insight: Rheumatoid Arthritis (G7) 4/1/2012 \| published by: Decision Resources ... campaigns and initiatives. The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-a inhibitors are firmly established as first-line biological agents. Biologics from other drug classes—the interleukin-6 inhibitor tocilizumab (Roche/Chugai’s Actemra/RoActemra), the ... \| more...	$3,000.00
Chronic Obstructive Pulmonary Disease 3/12/2012 \| published by: Decision Resources ... awareness of the disease continue, and the use of spirometry to diagnose COPD becomes more widespread. The expanding COPD patient population has great unmet need because truly disease-modifying pharmacotherapies are lacking; current treatments merely alleviate ... \| more...	$15,000.00
DRG Insight: Facial Injectables (US) 3/1/2012 \| published by: Decision Resources ... campaigns and initiatives. The North American facial injectable market—comprising revenues from the sale of botulinum toxin (BTX) and dermal filler products, including hyaluronic acid (HA) dermal fillers, and semi- and nonpermanent non-HA fillers —experienced a ... \| more...	$3,000.00
DRG Insights: Multiple Myeloma (G7) 3/1/2012 \| published by: Decision Resources ... campaigns and initiatives. The 2010 multiple myeloma (myeloma) market garnered impressive sales despite being a relatively small oncology indication in terms of incidence. Significant achievements in clinical practice over the last decade and the launches ... \| more...	$3,000.00
Hospital Insight Series: Complicated Skin and Skin Structure Infections (Europe) 12/30/2011 \| published by: Decision Resources ... Italy, and the UK) cSSSIs represent the third most commonly-treated type of infection treated in the hospital, and cSSSIs capture a significant proportion of the total hospital antibiotic cost. Gram-positive pathogens, specifically Staphylococcus aureus, are ... \| more...	$15,000.00
Diabetic Complications 12/29/2011 \| published by: Decision Resources ... leg amputations, kidney failure) and high levels of mortality. The economic burden of these complications, estimated at $58 billion in the United States in 2007, is considerable. The high unmet need for disease-modifying therapies that ... \| more...	$15,000.00
Community-Acquired Bacterial Pneumonia 12/28/2011 \| published by: Decision Resources ... to severe CABP population. Although the majority of CABP patients are treated in the outpatient setting, the inpatient setting represents more than half of the CABP market and will be the area of highest commercial ... \| more...	$15,000.00
Hospital Insight Series: MRSA Infections (Europe) 12/28/2011 \| published by: Decision Resources ... MRSA’s decreased susceptibility to IV vancomycin, the mainstay drug for the treatment of MRSA, poses significant challenges in the treatment of MRSA infections, yet provides opportunities for the uptake of other and emerging MRSA therapies ... \| more...	$15,000.00
How Will New Entrants Alter the Biologics Landscape in Ankylosing Spondylitis and Psoriatic Arthritis? A European Physician and Payer Perspective 12/21/2011 \| published by: Decision Resources ... TNF-a inhibitors are currently marketed for PsA and AS, with a fifth – UCB/Otsuka’s Cimzia – in Phase III trials for PsA and axial spondyloarthritis (SpA; includes AS and undifferentiated axial SpA). The lack of ... \| more...	$10,000.00
Special Report: Thought-Leader Opinion on the Current and Future Landscape of the Age-Related Macular Degeneration Market 12/7/2011 \| published by: Decision Resources ... is the leading cause of irreparable vision loss in the United States. Interviewed U.S. experts indicate substantial unmet needs in current AMD treatment. With only a few approved therapies, this market presents a big opportunity ... \| more...	$9,200.00
Special Report: Market Opportunities in Symptomatic Treatments of Multiple Sclerosis 12/7/2011 \| published by: Decision Resources ... up the crop of new niche agents in the United States indicated specifically for the treatment of individual symptoms that commonly occur in patients with this chronic disease. Although these agents are available, demand for ... \| more...	$9,200.00
Addiction Disorders 12/5/2011 \| published by: Decision Resources ... particular, more therapies to treat nicotine, alcohol, and psychostimulant addiction are areas of high unmet need through 2020. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| more...	$15,000.00
ChartTrends: Nephrology in Latin America 2011 12/1/2011 \| published by: Decision Resources ... values Quantify treatment prevalence of anemia medications Objective 4: Outline the selection process for ESA and IV Iron medications in dialysis patients What factors drive brand selection (i.e. co-morbidities, concomitant therapies, lab value ranges, disease ... \| more...	$15,000.00
ChartTrends®: Bone and Mineral Metabolism in CKD-ND 2011 12/1/2011 \| published by: Decision Resources ... (CKD) patient records. BioTrends has been covering the US Dialysis and CKD markets since 2004. This will be the sixth wave of the ChartTrends report. Please note, the PDF e-mail from publisher version of this ... \| more...	$15,000.00
ChartTrends®: Ulcerative Colitis 2011 12/1/2011 \| published by: Decision Resources ... for UC patients Use and frequency of laboratory assessments; laboratory values and diagnostic tests Frequency of office visits Understand the selection process for UC treatments and medications How are UC patients managed therapeutically? Was baseline ... \| more...	$15,000.00
Special Report: Patterns of Generic Erosion: An International Chartbook 12/1/2011 \| published by: Decision Resources ... of ten drugs-five cardiometabolic agents and five central nervous system (CNS) therapies-that have lost market exclusivity in recent years shows enormous variations in originator brands' market share in the United States and the five largest ... \| more...	$9,200.00
Special Report: Chartbook of International Pharmaceutical Prices 12/1/2011 \| published by: Decision Resources ... be aware of international price differentials. Many studies have compared retail prices in different countries, but international comparisons of pharmaceutical prices at the ex-manufacturer level are relatively uncommon. This chartbook-our eighth annual analysis of international ... \| more...	$9,200.00
Market-Changing Emerging Agents, 2012: The Evolving Blockbuster Model 12/1/2011 \| published by: Decision Resources ... foresees five agents reaching the market in 2012 that will earn blockbuster sales (sales of $1 billion annually) at some point in the next five years. Our profiles of these drugs highlight the marketplace characteristics ... \| more...	$4,600.00
LaunchTrends®: Victrelis & Incivek (Wave 3) 2011 12/1/2011 \| published by: Decision Resources ... the trial and usage of Victrelis & Incivek among Gastroenterologists and Hepatologists for the treatment of Hepatitis C. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| more...	$15,000.00
ChartTrends®: Lupus/SLE (US) 2011 12/1/2011 \| published by: Decision Resources ... syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, ... \| more...	$15,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >

Decision Resources

List of reports from Decision Resources

Research assistance

Join Alert Me now!